Therapeutic Efficacy of an Anti-P116-661 Polyclonal Antibody Against Mycoplasma pneumoniae Infection
Open Access
Abstract
The aim of this study was to investigate the therapeutic potential of a polyclonal antibody against the Mycoplasma pneumoniae (MP) P116-661 protein. A polyclonal antibody against the P116-661 protein was obtained by immunizing New Zealand white rabbits, and its therapeutic effects were systematically evaluated by various experimental methods. An immunofluorescence assay was used to detect the inhibitory effect of the P116-661 polyclonal antibody on the adhesion of MP cells to A549 cells. ELISAs and Western blotting were used to analyze the expression levels of inflammatory factors, such as IL-6 and TNF-α, in Beas-2b cells and model mice after MP infection. HE staining was used to observe pathological changes in the lung tissue of the infected mice. The results showed that the P116-661 polyclonal antibody effectively inhibited the adhesion of MP cells to A549 cells. It significantly reduced the secretion levels of inflammatory factors, such as IL-6 and TNF-α, in Beas-2b cells and mice after MP infection. Moreover, the antibody significantly improved the pathological damage to the lungs that was caused by MP infection in mice. This study confirms that the P116-661 polyclonal antibody has good therapeutic effects in vitro and in vivo, providing a new experimental basis for immunotherapy against MP infection.Keywords
This publication has 35 references indexed in Scilit:
- Disease burden and macrolide resistance of Mycoplasma pneumoniae infection in adults in the Asia-Pacific regionInternational Journal of Antimicrobial Agents, 2024
- Current status of Mycoplasma pneumoniae infection in ChinaWorld Journal of Pediatrics, 2024
- Insight into the Pathogenic Mechanism of Mycoplasma pneumoniaeCurrent Microbiology, 2022
- Seroprevalence of Kaposi's sarcoma‐associated herpesvirus and risk factors in Jiuquan area, ChinaJournal of Medical Virology, 2022
- Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae InfectionsJAMA Network Open, 2022
- Rational stepwise approach for Mycoplasma pneumoniae pneumonia in childrenJournal of Microbiology, Immunology and Infection, 2021
- T-B cell epitope peptides induce protective immunity against Mycoplasma pneumoniae respiratory tract infection in BALB/c miceImmunobiology, 2021
- Combined vitamin C, hydrocortisone, and thiamine therapy for patients with severe pneumonia who were admitted to the intensive care unit: Propensity score-based analysis of a before-after cohort studyJournal of Critical Care, 2018
- Development of protective anti-Mycoplasma pneumoniae antibodies after immunization of guinea pigs with the combination of a P1-P30 chimeric recombinant protein and chitosanMicrobial Pathogenesis, 2013
- Production of Polyclonal AntiseraCurrent Protocols in Immunology, 1995